ClinicalTrials.gg
CompletedNCT06342700Updated Sep 3, 2025

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

A Phase 1 interventional study of Rilzabrutinib crystalline form and Rilzabrutinib amorphous form in Autoimmune Disorder and Healthy Volunteers, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.

Enrollment
171st of 243
28 · median 53
Started
2024
with 22 others
Phase 1
62 of 341
16 open now
Registered
287th of 341
by date

Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 171st largest by enrollment of the 243 interventional ones that give a count, is one of 23 that started in 2024, is one of 62 in phase 1, and was the 287th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Autoimmune Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a cross-over, Phase 1, 4-arm study. The purpose of this study is to measure the relative bioavailability and food effect of crystalline formulation rilzabrutinib and amorphous formulation rilzabrutinib in healthy male and female participants aged 18 to 55 years of age.

The total study duration per participant is expected to be up to 36 days, including:

  • Screening: up to 4 weeks
  • Treatment periods: once successfully screened, enrolled participants will be randomized to 1 of 4 treatment sequences with 4 single dose treatment periods.
  • Washout: One day washout is planned after each treatment period hence providing 2 days between doses.
  • Safety follow-up: participants will be asked to participate in an end-of-study safety assessment upon discharge from the clinical study unit, ie, on Day 8 of the study.
03

Conditions studied

  • Autoimmune Disorder
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, (BMI) between 18.0 and 32.0 kg/m2, inclusive
  • Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy participant. Hepatic transaminases (, alanine aminotransferase) should not exceed 1.25 × the upper laboratory norm (); total should not exceed 1 × ULN
  • Willing to abstain from using tobacco or nicotine-containing products or consuming alcohol from check-in (Day -1) until discharge at end-of-study visit
  • Willing to abstain from taking any prescription drugs, dietary supplements, or non-prescription drugs within 14 days or 5 half-lives, whichever, is longer, prior to the first dose of study drug through the follow-up phone call. Use of hormonal and aspirin (at doses of ≤2000 mg/day) or ibuprofen (at doses of ≤1200 mg/day) are allowed prior to and during the study
  • Negative urine drug/alcohol testing at screening and check-in (Day -1). Screening urine drug/alcohol testing may be repeated once if deemed appropriate by the site Investigator
  • Willing to abstain from consuming grapefruit, star fruit, or Seville orange-containing products from 14 days prior to first dose of study drug until discharge from the clinical study unit

Exclusion criteria

Exclusion Criteria:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), infectious disease, or signs of acute illness
  • Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation [ECMO], mechanically ventilated)
  • Participant has a positive test result for SARS-CoV-2 (measured via Real-time Reverse Transcriptase Polymerase Chain Reaction [RT-PCR] or Rapid Antigen Test [RAT])
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month)
  • Blood donation, any volume, within 1 month before inclusion
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure \<30 mmHg within 3 minutes when changing from supine to standing position
  • Presence or history of drug , or allergic disease diagnosed and treated by a physician. Participants with known hypersensitivity to any component of the IMP formulation or allergic disease diagnosed and treated by a physician
  • History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis)
  • Regular intake of nicotine (via patch, smoking, vaping or other forms) more than 10 mg per day (based on the average nicotine content of 10-12 mg of nicotine per cigarette and inhalation of up to 2 mg of nicotine per cigarette), and unable to stop smoking during the study (occasional smoker can be enrolled)
  • Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
  • If female, pregnancy (defined as positive β-HCG blood test), or breast-feeding
  • Any medication (including St John's Wort or ginseng) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of aspirin/ibuprofen, hormonal , and menopausal hormone replacement therapy
  • Any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion:

    • Non-, including COVID-19: last administration of a vaccine within 4 weeks before randomization
    • Live vaccines: last administration of a vaccine within 3 months before randomization
  • Positive result on any of the following tests: surface antigen (HBs Ag), anti- virus (anti-HCV) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
  • Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates)
  • Positive alcohol breath or alcohol urine test
  • Positive pregnancy test
  • Gilbert's Syndrome

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Treatment A: SAR444671 amorphous fasted

    Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period

    Drug: Rilzabrutinib amorphous form

  • Experimental
    Treatment B: SAR444671 crystalline fasted

    Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fasted conditions on Day 1 for one period

    Drug: Rilzabrutinib crystalline form

  • Active comparator
    Treatment C: SAR444671 amorphous fed

    Participants will receive single oral dose of amorphous tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period

    Drug: Rilzabrutinib amorphous form

  • Experimental
    Treatment D: SAR444671 crystalline fed

    Participants will receive single oral dose of crystalline tablet formulation rilzabrutinib (SAR444671) under fed conditions on Day 1 for one period

    Drug: Rilzabrutinib crystalline form

Interventions

06

What researchers measure

Primary outcomes

  1. Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fasted state

    Cmax: maximum plasma concentration

    Time frame: Day 1 to Day 8

  2. Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fasted state

    AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 8

  3. Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fasted state

    AUC: area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fed state

    Cmax: maximum plasma concentration

    Time frame: Day 1 to Day 8

  2. Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fed state

    AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 8

  3. Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fed state

    AUC: area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1 to Day 8

  4. Food effects as assessed by rilzabrutinib Cmax following administration of the test and reference formulations under the fed versus fasted state

    Cmax: maximum plasma concentration

    Time frame: Day 1 to Day 8

  5. Food effects as assessed by rilzabrutinib AUClast following administration of the test and reference formulations under the fed versus fasted state

    AUClast: area under the plasma concentration versus time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 8

  6. Food effects as assessed by rilzabrutinib AUC following administration of the test and reference formulations under the fed versus fasted state

    AUC: area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1 to Day 8

  7. Number of participants with adverse events, treatment-emergent adverse events, serious adverse events and adverse events of special interest

    Time frame: Day 1 to Day 8

07

Study locations

1 site
  • Nucleus Network Site Number : 8400001
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2024, 0 months.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 0 months is below that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Apr 2, 2024
StartActual
Mar 25, 2024
Primary completionActual
Apr 23, 2024
CompletionActual
Apr 23, 2024
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342700
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Mar 25, 2024
Primary completion
Apr 23, 2024
Completion
Apr 23, 2024
Last update
Sep 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion